All News

Why did this patient's warfarin dose triple?

Top news of the day from across the health care industry.

Benzodiazepines are involved in over 30% of opioid overdoses. It is important to learn about this combination and how to counsel patients.

The IAVI WOO1 study is one of the first clinical trials of a native-like Env trimer and the first time that this particular trimer is being evaluated in humans

This article will describe the unusual discovery of 5 commonly prescribed medications, many of which were through serendipitous events.

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

Study data suggest the drug helps reduce the risk of major adverse cardiovascular event in certain patients.

The goals are to assess the candidate’s safety and to determine if the vaccination induces the human immune system to produce proteins called neutralizing antibodies.

The National Rosacea Society (NRS) has designated April as Rosacea Awareness month to improve education of rosacea.

The combination therapy reduced the risk of squamous cell carcinoma development on the face and scalp by approximately 75% in the study.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care industry.

With this approval, certolizumab pegol becomes the first FDA-approved therapy for this type of axSpA, filling an unmet clinical need for treatment options, according to the release.

The action follows discontinuation of quinidine, the only FDA-approved intravenous antimalarial drug in the United States.